Provided by Tiger Fintech (Singapore) Pte. Ltd.

iTeos Therapeutics

10.11
+0.01500.15%
Post-market: 10.09-0.0200-0.20%17:42 EDT
Volume:1.06M
Turnover:10.68M
Market Cap:446.57M
PE:-3.27
High:10.11
Open:10.10
Low:10.08
Close:10.10
Loading ...

GSK, iTeos Therapeutics End Belrestotug Development Program

MT Newswires Live
·
13 May

ITeos, GSK discontinue lung cancer therapy development

Reuters
·
13 May

Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?

Zacks
·
02 May

iTeos Therapeutics Reports Q1 2025 Financial Results

TIPRANKS
·
30 Apr

iTeos Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
29 Apr

iTeos Therapeutics (ITOS) Receives a Buy from Piper Sandler

TIPRANKS
·
29 Apr

iTeos Therapeutics reports Q1 EPS (80c), consensus (90c)

TIPRANKS
·
29 Apr

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire
·
29 Apr

Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year

Simply Wall St.
·
19 Apr

iTeos Therapeutics (ITOS) Gets a Buy from Piper Sandler

TIPRANKS
·
31 Mar

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

GlobeNewswire
·
26 Mar

iTeos Therapeutics: Poised for Success with Anti-TIGIT Therapies Amidst Competitive Landscape

TIPRANKS
·
07 Mar

iTeos Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
07 Mar

iTeos Therapeutics price target lowered to $17 from $19 at Wells Fargo

TIPRANKS
·
06 Mar

Promising Developments and Strategic Updates Drive Buy Rating for iTeos Therapeutics

TIPRANKS
·
06 Mar

iTeos Therapeutics: Undervalued with Promising Pipeline and Strong Financial Position

TIPRANKS
·
06 Mar

iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations

Simply Wall St.
·
06 Mar

BUZZ-iTeos Therapeutics rises after reporting narrower-than-expected quarterly loss

Reuters
·
06 Mar

Iteos Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Iteos Therapeutics Inc expected to post a loss of $1.06 a share - Earnings Preview

Reuters
·
05 Mar